Table 1 Baseline demographic, clinical and treatment characteristics of patient population
From: Coronavirus disease 19 in minority populations of Newark, New Jersey
Variable | Overall (n = 251) | Survivors (n = 154) | Non-survivors (n = 97) | p value |
|---|---|---|---|---|
Age (years) (m, IQR) | 62 (49–74) | 58 (46–69) | 68 (56–77) | < 0.0001 |
Sex (Male) | 129 (51) | 69 (45) | 60 (62) | 0.008 |
Race | ||||
African American | 210 (84) | 122 (79) | 88 (91) | 0.013 |
Hispanic | 41 (16) | 32 (21) | 9 (9) | |
BMI (kg/m2) | ||||
< 25 | 48 (19) | 27 (18) | 21 (22) | 0.445 |
25–29.9 | 83 (33) | 48 (31) | 35 (36) | |
30–35 | 61 (24) | 38 (25) | 23 (24) | |
> 35 | 59 (24) | 41 (27) | 18 (19) | |
Insurance Status | ||||
Commercial | 113 (45) | 67 (44) | 46 (47) | 0.655 |
Medicare/Medicaid | 86 (35) | 52 (34) | 34 (35) | |
Charity Care/Uninsured | 51 (20) | 34 (22) | 17 (18) | |
Self-reported exposure | ||||
Yes | 65 (26) | 39 (25) | 26 (27) | 0.795 |
History of | ||||
Hypertension | 175 (70) | 98 (66) | 77 (80) | 0.016 |
Diabetes Mellitus | 115 (46) | 65 (45) | 50 (52) | 0.269 |
CAD | 49 (20) | 20 (14) | 29 (30) | 0.003 |
CHF | 50 (20) | 25 (17) | 25 (26) | 0.095 |
CVA | 28 (11) | 12 (9) | 16 (16) | 0.056 |
COPD | 23 (9) | 13 (9) | 10 (10) | 0.754 |
HIV | 13 (5) | 12 (8) | 1 (1) | 0.008 |
CKD | 46 (18) | 17 (12) | 29 (30) | 0.005 |
Malignancy | 22 (9) | 8 (6) | 14 (14) | 0.021 |
Duration of Symptoms (d) | 4 (2–7) | 4 (3–7) | 3 (2–7) | 0.189 |
Vital signs at the time of presentation | ||||
Fever (> 100.4F) | 143 (57) | 89 (58) | 54 (56) | 0.741 |
HR > 125 bpm | 16 (6) | 6 (6) | 10 (6) | 0.922 |
RR > 24 bpm | 55 (22) | 28 (29) | 27 (18) | 0.036 |
MAP < 65 | 9 (4) | 3 (3) | 6 (4) | 0.922 |
Chest Imaging features | ||||
Consolidation | 48 (19) | 27 (22) | 21 (22) | 0.509 |
Ground glass Opacities | 136 (54) | 87 (56) | 49 (51) | 0.385 |
Bilateral Infiltrates | 192 (76) | 122 (79) | 70 (73) | 0.271 |
Treatment | ||||
Chloroquine | 186 (74) | 102 (72) | 84 (92) | 0.001 |
Remdesivir | 2 (1) | 2 (2) | 0 (0) | 0.157 |
Steroids | 35 (14) | 9 (6) | 26 (28) | < 0.001 |
Tociluzumab | 39 (16) | 16 (12) | 23 (28) | 0.002 |
*Antibiotics | 204 (81) | 118 (77) | 86 (91) | 0.004 |